Is there a future for AKT inhibitors in the treatment of cancer?

Abstract

An AKT inhibitor plus an antiestrogen exhibited no significant clinical activity in patients with ER+/HER2- breast cancer despite laboratory studies supporting an antitumor effect for both drugs combined. These results raise concerns about the development of AKT inhibitors in unselected patients whose tumors have unknown dependence on the PI3K/AKT pathway.